| Attributes | Values |
|---|
| rdf:type
| |
| Description
| - Pacienti s vysoce rizikovým Difuzním velkobuněčným lymfomem (DLBCL) mohou profitovat s léčby vysoce dávkovanou chemoterapií (HDT) následovanou autologní transplantací kostní dřeně (ASCT). Hodnotili jsme soubor 55 pacientů s DLBCL léčených HDT a ASCT v období od března 1999 až do července 2006. Po indukční chemoterapii s rituximabem (44%) nebo bez imunoterapie (56%), 36 pacientů (65%) dosáhlo parciální remise a 19 pacientů (35%) kompletní remise. Po následné autologní transplantaci kostní dřeně splnilo kriteria kompletní remise 69% pacientů, 22% pacientů jsme hodnotili jako nejistou kompletní remisi, 7% pacientů zůstalo v parciální remisi a 1 pacient (2%) zrelaboval. Celkové přežití 55 transplantovaných pacientů v 5 letech je 85% a přežití bez případu je 76%. Tyto výsledky ukazují, že léčba rizikových pacientů s Difuzním velkobuněčným lymfomem do 65 let vysoce dávkovanou chemoterapií následovanou autologní transplantací kostní dřeně v 1. linii představuje efektivní terapeutický přístup. (cs)
- Introduction: Improved survival has been observed in poor-risk diffuse large B-cell lymphoma (DLBCL) patients when treated with high-dose chemotherapy followed autologous transplantation (ASCT). Materials and Methods: We evaluated the results of HDT and ASCT in 55 patients treated between May 1999 and July 2006 with confimed DLBCL. Results: 36 patients (65%) had a partial response (PR) and 19 patiennts (35%) reached a complete remission (CR) after induction treatment with (44%) or without (56%) concomitant rituximab ? immunotherapy. After HDT and ASCT 69% patients fulfilled the criteria of CR, 22% patients ahd and unconfirmedCR (Cru), 7% patients were still only in PR and 1 patient (2%) relapsed. The 5-year event-free survival (EFS) of the 55 transplanted patients was 76% and the 5-year overall survival (OS) was 85%. EFS and OS rates differed significantly only between patients younger than 40 years and older groups (p=0.022 and p=0.046, respectively). Conclusion: These results shows that first-li
- Introduction: Improved survival has been observed in poor-risk diffuse large B-cell lymphoma (DLBCL) patients when treated with high-dose chemotherapy followed autologous transplantation (ASCT). Materials and Methods: We evaluated the results of HDT and ASCT in 55 patients treated between May 1999 and July 2006 with confimed DLBCL. Results: 36 patients (65%) had a partial response (PR) and 19 patiennts (35%) reached a complete remission (CR) after induction treatment with (44%) or without (56%) concomitant rituximab ? immunotherapy. After HDT and ASCT 69% patients fulfilled the criteria of CR, 22% patients ahd and unconfirmedCR (Cru), 7% patients were still only in PR and 1 patient (2%) relapsed. The 5-year event-free survival (EFS) of the 55 transplanted patients was 76% and the 5-year overall survival (OS) was 85%. EFS and OS rates differed significantly only between patients younger than 40 years and older groups (p=0.022 and p=0.046, respectively). Conclusion: These results shows that first-li (en)
|
| Title
| - High-dose therapy and autologous transplantation in poor prognosis patients with diffuse large B-cell lymphoma in first remission
- Vysoce dávkovaná chemoterapie a autologní transplantace u pacientů s rizikovým Difuzním velkobuněčným B lymfomem v 1. remisi (cs)
- High-dose therapy and autologous transplantation in poor prognosis patients with diffuse large B-cell lymphoma in first remission (en)
|
| skos:prefLabel
| - High-dose therapy and autologous transplantation in poor prognosis patients with diffuse large B-cell lymphoma in first remission
- Vysoce dávkovaná chemoterapie a autologní transplantace u pacientů s rizikovým Difuzním velkobuněčným B lymfomem v 1. remisi (cs)
- High-dose therapy and autologous transplantation in poor prognosis patients with diffuse large B-cell lymphoma in first remission (en)
|
| skos:notation
| - RIV/61989592:15110/07:00004380!RIV08-MSM-15110___
|
| http://linked.open.../vavai/riv/strany
| |
| http://linked.open...avai/riv/aktivita
| |
| http://linked.open...avai/riv/aktivity
| |
| http://linked.open...iv/cisloPeriodika
| |
| http://linked.open...vai/riv/dodaniDat
| |
| http://linked.open...aciTvurceVysledku
| |
| http://linked.open.../riv/druhVysledku
| |
| http://linked.open...iv/duvernostUdaju
| |
| http://linked.open...titaPredkladatele
| |
| http://linked.open...dnocenehoVysledku
| |
| http://linked.open...ai/riv/idVysledku
| - RIV/61989592:15110/07:00004380
|
| http://linked.open...riv/jazykVysledku
| |
| http://linked.open.../riv/klicovaSlova
| - large B-cell lymphoma; autolous transplantation (en)
|
| http://linked.open.../riv/klicoveSlovo
| |
| http://linked.open...odStatuVydavatele
| - GB - Spojené království Velké Británie a Severního Irska
|
| http://linked.open...ontrolniKodProRIV
| |
| http://linked.open...i/riv/nazevZdroje
| |
| http://linked.open...in/vavai/riv/obor
| |
| http://linked.open...ichTvurcuVysledku
| |
| http://linked.open...cetTvurcuVysledku
| |
| http://linked.open...UplatneniVysledku
| |
| http://linked.open...v/svazekPeriodika
| |
| http://linked.open...iv/tvurceVysledku
| - Dušek, Ladislav
- Faber, Edgar
- Indrák, Karel
- Jarkovský, J.
- Jarošová, Marie
- Kubová, Zuzana
- Raida, Luděk
- Skoumalová, Ivana
- Vondráková, Jana
- Procházka, Vít
- Papajík, Tomáš
|
| http://linked.open...n/vavai/riv/zamer
| |
| issn
| |
| number of pages
| |
| http://localhost/t...ganizacniJednotka
| |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)